JP2017500299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500299A5 JP2017500299A5 JP2016536776A JP2016536776A JP2017500299A5 JP 2017500299 A5 JP2017500299 A5 JP 2017500299A5 JP 2016536776 A JP2016536776 A JP 2016536776A JP 2016536776 A JP2016536776 A JP 2016536776A JP 2017500299 A5 JP2017500299 A5 JP 2017500299A5
- Authority
- JP
- Japan
- Prior art keywords
- unit
- ligand
- drug
- drug conjugate
- conjugate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918539P | 2013-12-19 | 2013-12-19 | |
| US61/918,539 | 2013-12-19 | ||
| PCT/US2014/071593 WO2015095755A1 (en) | 2013-12-19 | 2014-12-19 | Methylene carbamate linkers for use with targeted-drug conjugates |
| TW103144705A TWI727919B (zh) | 2013-12-19 | 2014-12-19 | 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 |
| TW103144705 | 2014-12-19 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019041218A Division JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500299A JP2017500299A (ja) | 2017-01-05 |
| JP2017500299A5 true JP2017500299A5 (cg-RX-API-DMAC7.html) | 2018-02-01 |
| JP6701077B2 JP6701077B2 (ja) | 2020-05-27 |
Family
ID=60450371
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536776A Active JP6701077B2 (ja) | 2013-12-19 | 2014-12-19 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2019041218A Active JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2020109383A Active JP7229202B2 (ja) | 2013-12-19 | 2020-06-25 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2023020516A Withdrawn JP2023055973A (ja) | 2013-12-19 | 2023-02-14 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019041218A Active JP6784790B2 (ja) | 2013-12-19 | 2019-03-07 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2020109383A Active JP7229202B2 (ja) | 2013-12-19 | 2020-06-25 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
| JP2023020516A Withdrawn JP2023055973A (ja) | 2013-12-19 | 2023-02-14 | 標的化薬物結合体と使用するためのメチレンカルバメートリンカー |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11116847B2 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6701077B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102442906B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN105813653B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014369019B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2932647C (cg-RX-API-DMAC7.html) |
| IL (5) | IL290330B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX385651B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ721877A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201610465PA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI727919B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015095755A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201604564B (cg-RX-API-DMAC7.html) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| CA2954934C (en) | 2014-06-30 | 2023-09-26 | Glykos Finland Oy | Drug derivative and conjugates |
| TW201702260A (zh) | 2015-03-05 | 2017-01-16 | 賽倫斯有限責任公司 | 環肽類似物及其共軛物 |
| KR102847350B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법 |
| CN118105513A (zh) | 2015-11-25 | 2024-05-31 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
| EP3380125A4 (en) | 2015-11-25 | 2019-08-28 | LegoChem Biosciences, Inc. | CONJUGATES WITH PEPTIDE GROUPS AND RELATED METHODS |
| AU2017238246B2 (en) * | 2016-03-24 | 2021-04-01 | The Administrators Of The Tulane Educational Fund | Conjugates of tacrolimus, their compositions, and their uses |
| WO2017165851A1 (en) * | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
| WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| KR20190038579A (ko) * | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| US11254705B2 (en) | 2016-09-02 | 2022-02-22 | Sirenas Llc | Cyclic peptide analogs and conjugates thereof |
| BR112019006778A2 (pt) | 2016-10-18 | 2019-10-15 | Seattle Genetics Inc | Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco |
| CN118359705A (zh) | 2016-10-19 | 2024-07-19 | 英温拉公司 | 抗体构建体 |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| KR102085798B1 (ko) * | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| WO2018124758A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
| KR20190125310A (ko) * | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
| US11730822B2 (en) * | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| MA51189A (fr) | 2017-04-27 | 2020-03-04 | Seattle Genetics Inc | Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé |
| KR20200012876A (ko) * | 2017-05-02 | 2020-02-05 | 레볼루션 메디슨즈, 인크. | mTOR 억제제로서의 파라마이신 유사체 |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CA3126646A1 (en) | 2017-09-29 | 2019-04-04 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| TW201922782A (zh) | 2017-10-24 | 2019-06-16 | 美商麥珍塔治療學股份有限公司 | 去除cd117+細胞之組合物及方法 |
| KR20200094181A (ko) | 2017-11-29 | 2020-08-06 | 마젠타 테라퓨틱스 인코포레이티드 | Cd5+ 세포를 고갈시키기 위한 조성물 및 방법 |
| CA3084667A1 (en) | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
| CN111712507B (zh) * | 2017-12-21 | 2024-02-06 | 药物有限公司 | 改良药物口服生物有效性的方法 |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| EP3762037B1 (en) * | 2018-03-09 | 2023-12-27 | QuiaPEG Pharmaceuticals AB | Releasable antibody conjugates |
| BR112020020466A2 (pt) * | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| AU2019262979B2 (en) | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
| IL300091A (en) | 2018-05-01 | 2023-03-01 | Revolution Medicines Inc | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors |
| WO2019215510A2 (en) | 2018-05-09 | 2019-11-14 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| CN112566666A (zh) | 2018-05-14 | 2021-03-26 | 努瓦申生物公司 | 靶向抗癌核激素受体的化合物 |
| SG11202011984UA (en) | 2018-06-05 | 2020-12-30 | King S College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| TWI851577B (zh) * | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN112739340B (zh) | 2018-07-23 | 2025-05-13 | 海德堡医药研究有限责任公司 | 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| TWI834720B (zh) | 2018-09-12 | 2024-03-11 | 瑞典商奎亞培格製藥公司 | 可釋放glp-1共軛物 |
| JP2022500404A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用 |
| MY208067A (en) | 2018-12-21 | 2025-04-11 | Regeneron Pharma | Tubulysins and protein-tubulysin conjugates |
| EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
| AU2020274113A1 (en) | 2019-05-14 | 2021-11-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CR20220058A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos |
| JP7675060B2 (ja) | 2019-07-10 | 2025-05-12 | サイブレクサ ３，インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
| MX2022001719A (es) | 2019-08-15 | 2022-03-11 | Silverback Therapeutics Inc | Formulaciones de conjugados de benzazepina y usos de las mismas. |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| CA3152316A1 (en) * | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
| WO2021072330A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases |
| WO2021072203A1 (en) | 2019-10-09 | 2021-04-15 | Silverback Therapeutics, Inc. | Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof |
| US12502440B2 (en) | 2019-11-08 | 2025-12-23 | North Carolina State University | Cross-linking compounds and methods of use thereof |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
| CA3200812A1 (en) * | 2020-12-04 | 2022-06-09 | Qingsong GUO | Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof |
| US20240050584A1 (en) * | 2020-12-18 | 2024-02-15 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trop2 targeting antibody-drug conjugate, and preparation method and use therefor |
| WO2022126569A1 (zh) * | 2020-12-18 | 2022-06-23 | 上海复旦张江生物医药股份有限公司 | 一种靶向b7-h3的抗体药物偶联物、其制备方法及应用 |
| AR124475A1 (es) | 2020-12-23 | 2023-03-29 | Univ Muenchen Ludwig Maximilians | Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos |
| IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
| AU2022253474A1 (en) | 2021-04-08 | 2023-11-16 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| TW202304524A (zh) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
| AU2022262644A1 (en) | 2021-04-23 | 2023-11-09 | Genmab A/S | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| CA3218577A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| JP2024540536A (ja) | 2021-11-19 | 2024-10-31 | アーディアジェン コーポレーション | Ｇｐｃ３結合剤、そのコンジュゲートおよびその使用方法 |
| WO2023131219A1 (en) * | 2022-01-06 | 2023-07-13 | Virtuoso Binco, Inc. | Conjugates, compositions and methods of use |
| AU2023251200A1 (en) | 2022-04-07 | 2024-10-03 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
| CN119604293A (zh) | 2022-05-25 | 2025-03-11 | 锐新医药公司 | 用mTOR抑制剂治疗癌症的方法 |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| WO2024025396A1 (ko) * | 2022-07-28 | 2024-02-01 | 주식회사 레고켐 바이오사이언스 | 신규 오리스타틴 전구약물 |
| EP4583919A1 (en) | 2022-09-09 | 2025-07-16 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
| JP2025532285A (ja) * | 2022-09-30 | 2025-09-29 | システィミューン， インク． | 高安定性親水性リンカーユニットを有するアウリスタチン系薬物及びその複合体 |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
| KR20240159448A (ko) | 2023-04-28 | 2024-11-05 | 주식회사 에이비켐바이오 | 균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법 |
| KR20240159447A (ko) | 2023-04-28 | 2024-11-05 | 주식회사 에이비켐바이오 | 말레이미드 함유 링커-페이로드 접합체 |
| KR20250074353A (ko) | 2023-11-20 | 2025-05-27 | 주식회사 에이비켐바이오 | 높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도 |
| US20240423620A1 (en) | 2023-06-22 | 2024-12-26 | Cilag Gmbh International | Compressible surgical adjuncts, cartridges, and cartridge assemblies and methods of making surgical adjuncts |
| EP4543314A1 (en) * | 2023-06-22 | 2025-04-30 | Cilag GmbH International | Systems and methods for embedding medical additives into bioabsorbable materials |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| CN119424671A (zh) * | 2023-08-01 | 2025-02-14 | 上海新理念生物医药科技有限公司 | 含糖基吡啶型连接子的抗体药物偶联物 |
| WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927070A (en) * | 1972-05-08 | 1975-12-16 | Karoly Szabo | M-(3,3-disubstituted ureido) phenyl {8 (substituted)methyl{9 {0 carbamates |
| US5851527A (en) | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
| EP0848957A1 (en) * | 1995-09-08 | 1998-06-24 | Kanebo Ltd. | Fas LIGAND SOLUBILIZATION INHIBITOR |
| US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
| AU1607501A (en) | 1999-11-15 | 2001-05-30 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| HUE045882T2 (hu) * | 2004-03-23 | 2020-01-28 | Ascendis Pharma Gmbh | Polimer prodrug önmagát lehasító linkerrel |
| PT3248613T (pt) | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fármaco e beta-glucuronida |
| WO2007022493A2 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs, and derivatives |
| EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| EP2229187A2 (en) * | 2007-11-30 | 2010-09-22 | Bristol-Myers Squibb Company | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
| US20110152252A1 (en) * | 2007-12-18 | 2011-06-23 | Institut Curie | Shiga toxin b-subunit/chemotherapeutics conjugates |
| EP2240495B1 (en) * | 2008-02-01 | 2015-07-15 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| DK2566334T3 (en) * | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| JP6170497B2 (ja) | 2011-10-14 | 2017-07-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン |
| JP6399930B2 (ja) | 2011-10-14 | 2018-10-03 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| MX384366B (es) | 2012-05-15 | 2025-03-14 | Seagen Inc | Conjugados enlazadores auto-estabilizantes. |
| CA2890569C (en) * | 2012-11-05 | 2019-03-05 | Pfizer Inc. | Spliceostatin analogs |
| US9695189B2 (en) | 2013-03-01 | 2017-07-04 | Mark Quang Nguyen | Chemical crosslinkers and compositions thereof |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| TW201702260A (zh) | 2015-03-05 | 2017-01-16 | 賽倫斯有限責任公司 | 環肽類似物及其共軛物 |
-
2014
- 2014-12-19 CA CA2932647A patent/CA2932647C/en active Active
- 2014-12-19 CN CN201480066385.XA patent/CN105813653B/zh active Active
- 2014-12-19 KR KR1020167017938A patent/KR102442906B1/ko active Active
- 2014-12-19 KR KR1020247000133A patent/KR20240010081A/ko not_active Withdrawn
- 2014-12-19 SG SG11201610465PA patent/SG11201610465PA/en unknown
- 2014-12-19 NZ NZ721877A patent/NZ721877A/en unknown
- 2014-12-19 IL IL290330A patent/IL290330B2/en unknown
- 2014-12-19 AU AU2014369019A patent/AU2014369019B2/en active Active
- 2014-12-19 CN CN202010418302.6A patent/CN111558049B/zh active Active
- 2014-12-19 WO PCT/US2014/071593 patent/WO2015095755A1/en not_active Ceased
- 2014-12-19 MX MX2016007364A patent/MX385651B/es unknown
- 2014-12-19 CN CN202010417903.5A patent/CN111569086B/zh active Active
- 2014-12-19 TW TW103144705A patent/TWI727919B/zh active
- 2014-12-19 JP JP2016536776A patent/JP6701077B2/ja active Active
- 2014-12-19 KR KR1020227030682A patent/KR20220127364A/ko not_active Ceased
- 2014-12-19 IL IL301674A patent/IL301674A/en unknown
- 2014-12-19 US US15/106,272 patent/US11116847B2/en active Active
-
2016
- 2016-06-05 IL IL246015A patent/IL246015B/en active IP Right Grant
- 2016-06-06 MX MX2021010192A patent/MX2021010192A/es unknown
- 2016-07-05 ZA ZA2016/04564A patent/ZA201604564B/en unknown
-
2019
- 2019-03-07 JP JP2019041218A patent/JP6784790B2/ja active Active
- 2019-08-08 IL IL268595A patent/IL268595B/en active IP Right Grant
-
2020
- 2020-06-25 JP JP2020109383A patent/JP7229202B2/ja active Active
- 2020-07-06 ZA ZA2020/04099A patent/ZA202004099B/en unknown
- 2020-12-04 AU AU2020281140A patent/AU2020281140B2/en active Active
-
2021
- 2021-04-22 IL IL282581A patent/IL282581B/en unknown
- 2021-08-02 US US17/391,580 patent/US20220054650A1/en not_active Abandoned
-
2022
- 2022-12-06 AU AU2022283652A patent/AU2022283652B2/en not_active Expired - Fee Related
-
2023
- 2023-02-14 JP JP2023020516A patent/JP2023055973A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500299A5 (cg-RX-API-DMAC7.html) | ||
| RU2315782C2 (ru) | Высокомолекулярные производные камптотецинов | |
| He et al. | Rational design of a new self‐codelivery system from redox‐sensitive camptothecin–cytarabine conjugate assembly for effectively synergistic anticancer therapy | |
| Chytil et al. | New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting | |
| ES2551233T3 (es) | Métodos para la preparación de conjugados citotóxicos de maitansinoides y agentes que se fijan a las células | |
| ES2410591T3 (es) | Nuevo copolímero en bloque, preparación micelar y agente antineoplásico que lo contiene como principio activo | |
| CN101218280B (zh) | 胞苷代谢拮抗剂的聚合衍生物 | |
| EP2070971A1 (en) | Compound of resorcinol derivative with polymer | |
| Sedláček et al. | Polymer conjugates of acridine-type anticancer drugs with pH-controlled activation | |
| JP6867084B2 (ja) | 新規な陽イオン性ポリホスファゼン化合物、ポリホスファゼン−薬物コンジュゲート化合物およびその製造方法 | |
| KR20090009241A (ko) | 포도필로톡신류의 고분자 결합체 | |
| TW200836751A (en) | Polymeric derivative of nucleic acid metabolic antagonist | |
| US12338244B2 (en) | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | |
| WO2008076333A8 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
| WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
| KR20090066302A (ko) | 약제복합체용 블록 공중합체 및 의약조성물 | |
| KR20080106254A (ko) | 탁산류의 고분자 결합체 | |
| Williams et al. | RAFT‐Derived Polymer–Drug Conjugates: Poly (hydroxypropyl methacrylamide)(HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates | |
| Yurkovetskiy et al. | Synthesis of a macromolecular camptothecin conjugate with dual phase drug release | |
| KR20220054368A (ko) | Dna 손상 반응의 컨쥬게이션된 억제제 | |
| JP2022501341A (ja) | ポリマーベースの高分子プロドラッグ | |
| Mukaya et al. | Synthesis and characterization of water-soluble polyaspartamides containing platinum (II) complex and bisphosphonate as potential antimalarial drug | |
| CN110123759A (zh) | Umirolimus及其衍生物用于治疗癌症的用途 | |
| CN104981245A (zh) | 无副作用的抗癌剂 | |
| KR102462782B1 (ko) | 환원반응성 일산화질소 공여 화합물 및 전달체 시스템 |